Key result
Catheter-directed thrombolysis shows promising results in reducing postthrombotic syndrome after deep venous thrombosis, while the role of new oral factor X inhibitors remains to be determined.
Catheter-directed thrombolysis shows promise in reducing postthrombotic syndrome incidence after deep venous thrombosis, while the role of oral factor X inhibitors remains undetermined.
Requires prospective trials before considering catheter-directed thrombolysis for postthrombotic syndrome; leaves role of oral factor X inhibitors open.
Postthrombotic syndrome is the most common complication after deep venous thrombosis. Postthrombotic syndrome is a debilitating disease and associated with decreased quality of life and high healthcare costs. Postthrombotic syndrome is a chronic disease, and causative treatment options are limited. Prevention of postthrombotic syndrome is therefore very important. Not all patients develop postthrombotic syndrome. Risk factors have been identified to try to predict the risk of developing postthrombotic syndrome. Age, gender, and recurrent deep venous thrombosis are factors that cannot be changed. Deep venous thrombosis location and extent seem to predict severity of postthrombotic syndrome and are potentially suitable as patient selection criteria. Residual thrombosis and reflux are known to increase the incidence of postthrombotic syndrome, but are of limited use. More recently developed treatment options for deep venous thrombosis, such as new oral factor X inhibitors and catheter-directed thrombolysis, are available at the moment. Catheter-directed thrombolysis shows promising results in reducing the incidence of postthrombotic syndrome after deep venous thrombosis. The role of new oral factor X inhibitors in preventing postthrombotic syndrome is still to be determined.
No takes yet. Share an insight, caveat, or question.
Strijkers et al. (2016) conducted a review in Postthrombotic syndrome after deep venous thrombosis. Catheter-directed thrombolysis and new oral factor X inhibitors was evaluated. Catheter-directed thrombolysis shows promising results in reducing postthrombotic syndrome after deep venous thrombosis, while the role of new oral factor X inhibitors remains to be determined.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: